Logo

Top 20 Generics Pharma Companies Based on 2021 Revenue

Share this
Top 20 Generics Pharma Companies Based on 2021 Revenue

Top 20 Generics Pharma Companies Based on 2021 Revenue

Shots:

  • With an increased price range and the lack of accessibility of branded products, the generic version of these products has been established to be more affordable and accessible to patients, providers, and the healthcare system. Therefore, Generic medicines are a bioequivalent substitute for a marketed brand-name drug, developed after the expiry of the patent time
  • The generic version of these branded products had led to a surge of competition among generic players including innovator companies, in order to sustain themselves in the market. This year, Teva has secured the top position with total revenue of $8.99B, followed by Sandoz and Viatris
  • Our team at PharmaShots has compiled a list of the top 20 generic companies based on their 2021 generic segment revenue

Generic Segment Revenue: $0.26B

Founded Year: 1984

Market Cap: $2.32B

Total Employees: ~13,600

Headquarters: Mumbai, India

Stock Exchange: NSE

Piramal Healthcare is an Indian pharma company that provides development and manufacturing solutions through a globally integrated network of facilities across drug life cycles to innovators and generic companies. The company focuses on the development of products within the therapeutic areas including Cardiovascular, Inflammation, and Infectious Diseases. The company’s 2021 revenue was boosted by 18.2% vs 2020. On Mar’21, Primal acquired a 100% stake in Hemmo Pharma that added peptide API development and manufacturing capabilities to the company.

Generic Segment Revenue: $0.74B

Founded Year: 1997

Market Cap: $0.02B

Total Employees: ~3,000

Headquarters: Dublin, Ireland

Stock Exchange: NASDAQ

Endo International is a global pharma company that develops and delivers generic as well as branded injectable products under its product portfolio comprising sterile injectables, alternative dosage forms, and other products within therapeutic areas including Endocrinology, Medical Aesthetics, Orthopaedics, and Urology. The company’s 2021 revenue dropped by 5.1% vs 2020. On Sep’21, Endo launched its generic version of Chantix in the US after receiving the ANDA approval.

Generic Segment Revenue: $0.79B

Founded Year: 1973

Market Cap: $1.64B

Total Employees: ~95,400

Headquarters: Paris, France

Stock Exchange: NASDAQ

Sanofi is a multinational biopharma company based in France that focuses on providing treatment options for therapeutic areas including Oncology, Cardiovascular, Neurology, Immunology, and Inflammation. The company’s 2021 revenue decreased by 30.1% vs 2020. On Sep’21, Sanofi entered into a settlement agreement with Breckenridge to launch Teriflunomide Tablets which is a generic version of Aubagio.

Generic Segment Revenue: $1.12B 

Founded Year: 1959

Market Cap: $6.63B

Total Employees: ~13,900

Headquarters: Ahmedabad, India

Stock Exchange: NSE

Torrent Pharma is an Indian pharma company that is committed to the discovery, development, and commercialization of products for therapeutic areas including Cardiovascular, Central Nervous Systems, Gastro-Intestinal, and Neutraceuticals. The company’s 2021 revenue increased by 2.7% vs 2020. On May’21, Torrent Pharma entered into a licensing agreement with Eli Lilly to develop baricitinib for the treatment of COVID-19 in India.

Generic Segment Revenue: $1.37B

Founded Year: 2002

Market Cap: $0.62B

Total Employees: ~7,000

Headquarters: New Jersey, United States

Stock Exchange: NYSE

Amneal is an American pharma company obligated to deliver essential medicines across therapeutic areas including Cardiovascular, Central Nervous System, Oncology, Inflammation, Anti-Infective, Dermatology, Endocrinology, Diabetes, and Urology. The company’s 2021 revenue decreased by 2.2% vs 2020. On Nov’21, Amneal received ANDA approval from the US FDA for difluprednate ophthalmic emulsion 0.05%, the generic version of Durezol for the treatment of ocular surgery-associated inflammation and pain. 

Generic Segment Revenue: $1.51B

Founded Year: 1895

Market Cap: N/A

Total Employees: ~12,500

Headquarters: Bad Vilbel, Germany

Stock Exchange: N/A

Stada is a German pharma company that is committed to the development and manufacturing of therapeutic products under the segments, generics, consumer healthcare, and speciality. The company’s 2021 revenue decreased by 5.0% vs 2020. On Oct’21, Stada launched its triple combination product containing levodopa, carbidopa, and entacapone in Germany and Australia for the treatment of Parkinson’s disease.

Generic Segment Revenue: $1.53B

Founded Year: 1984

Market Cap: $8.59B

Total Employees: ~24,800

Headquarters: Hyderabad, India

Stock Exchange: NSE

Dr.Reddy’s Laboratories is an Indian pharma company that works towards the development of generic formulations and proprietary products across therapeutic areas including Oncology, Cardiovascular, Dermatology, Gastrointestinal, Diabetics, Nephrology, and pain management. The company’s 2021 revenue inclined by 5.5% vs 2020. On Oct’21, Dr. Reddy’s received ANDA approval from the US FDA for Lenalidomide Capsules, a bioequivalent of Revlimid.

Generic Segment Revenue: $1.59B

Founded Year: 1929

Market Cap: $1.26B

Total Employees: ~2,400

Headquarters: Osaka, Japan

Stock Exchange: TYO

Sawai is a Japanese pharma company dedicated to the manufacturing and commercialization of generic and proprietary products in therapeutic areas including Cardiovascular, Diabetes, Antihyperlipidemic, Anti-cancer, and OTC drugs. The company’s 2021 revenue declined by 5.9% vs 2020. On Aug’21, Sawai pharma received approval for four generic products including Levetiracetam (tablets/granular tablets/dry syrup), Ambrisentan tablets, Olopatadine ophthalmic solution, and Iguratimod tablets by the MHLW. 

Generic Segment Revenue: $1.66B

Founded Year: 1999

Market Cap: $11.28B

Total Employees: ~ 316,100

Headquarters: Bad Homburg, Germany

Stock Exchange: ETR

Fresenius Kabi is a global healthcare company based in Germany that provides IV Generic Drugs, Infusion Therapies, and Clinical Nutrition Products across multiple therapeutic areas including Autoimmune Diseases and Oncology. The company’s 2021 revenue decreased by 10.7% vs 2020. On Mar’21, Fresenius Kabi launched Foscarnet Sodium Injection in the US which is the generic version of Foscavir for the treatment of immune-compromised patients.

Generic Segment Revenue: $1.68B

Founded Year: 1977

Market Cap: $1.32B

Total Employees: ~14,000

Headquarters: Mumbai, India

Stock Exchange: NSE

Glenmark is a global pharma company that oscillates around the production of therapeutic options for unmet medical needs in the therapeutic areas including Oncology, Respiratory, and Dermatology. The company’s 2021 revenue was boosted by 12.7% vs 2020. On Jun’21, Glenmark launched Tiogiva, a bioequivalent version of Tiotropium Bromide dry powder inhaler in the UK for the treatment of COPD.

Generic Segment Revenue: $1.78B

Founded Year: 1954

Market Cap: $2.87B

Total Employees: ~12,600

Headquarters: Novo Mesto, Slovenia

Stock Exchange: LJSE

Krka is an international generic pharma company that is focused on the production and commercialization of prescription, and non-prescription products across therapeutic areas including Cardiovascular, Respiratory, Urinary Tract, and Central Nervous System Diseases along with animal health products. The company’s 2021 revenue decreased by 5.3% vs 2020. During the fiscal year 2021, Krka launched new products including Algominal, Doreta SR, Atixarso, Pemetrexed Krka, and Anastrozole Krka.

Generic Segment Revenue: $2.05B

Founded Year: 1968

Market Cap: $3.77B

Total Employees: ~19,800

Headquarters: Mumbai, India

Stock Exchange: NSE

Lupin is an Indian multinational pharma company obligated to provide a diverse product portfolio comprising Generics, Biosimilars & Specialty Products in therapeutic areas including Anti-Tuberculosis, Respiratory, Diabetes, Cardiology, CNS, Gynaecology, and Gastrointestinal. The company’s 2021 revenue declined by 5.1% vs 2020. On Feb’21, Lupin received ANDA approval from the US FDA for Droxidopa Capsules, a generic equivalent of Northera Capsules for the treatment of Neurological Diseases.

Generic Segment Revenue: $2.36B

Founded Year: 1997

Market Cap: $15.92B

Total Employees: ~9,100

Headquarters: Durban, South Africa

Stock Exchange: JSE

Aspen is a global pharma company that is focused on the development and commercialization of generic and branded products along with sterile injections, oral solid doses, liquids, semi-solids, biologicals, and APIs. The company’s 2021 revenue declined by 10.6% vs 2020. On Jul’21, Aspen initiated the supply of COVID vaccines developed by J&J to South Africa.

Generic Segment Revenue: $2.55B

Founded Year: 1978

Market Cap: $3.19B

Total Employees: ~8,700

Headquarters: London, United Kingdom

Stock Exchange: LON

Hikma is a multinational pharma company based in the UK committed to the discovery, development, and commercialization of generic and branded pharma products for therapeutic areas including Cardiovascular, CNS, Diabetes, Oncology, Respiratory, and Anti-infectives. The company’s 2021 revenue was boosted by 9.0% vs 2020. On Mar’21, Hikma received ANDA approval from the US FDA for its Droxidopa Capsules for the treatment of patients with symptomatic neurogenic orthostatic hypotension. The company also launched this generic equivalent of Northera Capsules in the US on Mar’21.

Generic Segment Revenue: $2.87B

Founded Year: 1935

Market Cap: $10.93B

Total Employees: ~25,900

Headquarters: Mumbai, India

Stock Exchange: NSE

Cipla is a global pharma company that is focused on the development of complex generics for therapeutic areas including Respiratory, Anti-retroviral, Urology, Cardiology, Anti-infective, and CNS. The company’s 2021 revenue increased by 10.0% vs 2020. On Aug’21, Cipla received ANDA approval from the US FDA for Difluprednate Ophthalmic Emulsion 0.05%, a generic version of Durezol for the treatment of pain associated with ocular surgery.

Generic Segment Revenue: $3.09B

Founded Year: 1986

Market Cap: $3.66B

Total Employees: ~31,400

Headquarters: Hyderabad, India

Stock Exchange: NSE

Aurobindo Pharma is an Indian multinational pharma company that works towards the development and manufacturing of generic products across therapeutic areas including Neurosciences, Cardiovascular, Anti-retroviral, Diabetes, and Gastroenterology. The company’s 2021 revenue declined by 8.6% vs 2020. On Feb’21, Aurobindo received ANDA approval from the US FDA for Droxidopa Capsules which is a generic equivalent of Northera for the treatment of Neurological Diseases. 

Generic Segment Revenue: $5.06B

Founded Year: 1983

Market Cap: $27.73B

Total Employees: ~38,000

Headquarters: Mumbai, India

Stock Exchange: NSE

Sun Pharma is an Indian pharma company focused on the manufacturing of pharma products including generics, branded generics, specialty, complex or difficult-to-make technology-intensive products OTC, ARVs, APIs, and Intermediates for chronic and acute therapies. The company’s 2021 revenue increased by 11.9% vs 2020. On Dec’15, Sun Pharma received ANDA approval from the US FDA for the generic Amphotericin B Liposome Injection, a generic equivalent of AmBisome.

Generic Segment Revenue: $5.63B

Founded Year: 2020

Market Cap: $11.39B

Total Employees: ~37,000

Headquarters: Pennsylvania, United States

Stock Exchange: NASDAQ

Viatris is an American healthcare company that provides global key brands and generics including branded and complex generics along with biosimilars, and OTC offerings across therapeutic areas including Cardiovascular, Oncology, Immunology, CNS, Gastroenterology, Dermatology, and Respiratory. The company’s 2021 revenue was boosted by 6.6% vs 2020. On Mar’21, Viatris and Kindeva reported the tentative ANDA approval by the US FDA for its generic version of Symbicort for the treatment of COPD.

Generic Segment Revenue: $7.09B

Founded Year: 2003

Market Cap: $183.83B

Total Employees: ~15,000

Headquarters: Basel, Switzerland

Stock Exchange: SWX

Sandoz is a global pharma company that oscillates around the development, manufacturing, and commercialization of generic medicines and intermediary products across Retail Generics, Anti-Infectives, and Biopharmaceuticals. The company’s 2021 revenue declined by 2.1% vs 2020. On Jul’21, Sandoz launched Ferumoxytol in the US for the treatment of iron deficiency anaemia. 

Generic Segment Revenue: $8.99B

Founded Year: 1976

Market Cap: $9.38B

Total Employees: ~37,500

Headquarters: Petah Tikva, Israel

Stock Exchange: NYSE

Teva is an Israeli multinational pharma company that focuses on the development of specialty medicines, OTC, biopharma, and generic products operated through its segments in North America, Europe, and International Markets with the aim to increase patient access. The company’s 2021 revenue declined by 3.4% vs 2020. On Mar’21, Teva launched its generic version of Azopt (brinzolamide ophthalmic suspension) 1% in the USA for the treatment of ocular hypertension.

Sources:

  • Annual reports
  • SEC Filings
  • Press releases
  • Company websites

Market Cap Source: Google finance (12th Oct 2022)

Currency Conversion: X-Rates (12th Oct 2022)

Note:

  • All revenues are reported in $B
  • The revenue for Sawai Increased in JPY but Decreased in USD (Due to Currency Rate Drop)
  • The revenue for Krka Increased in EUR but Decreased in USD (Due to Currency Rate Drop)
  • The revenue for Aurobindo Pharma Increased in INR but Decreased in USD (Due to Currency Rate Drop)

Shivani

Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions